Latest Headlines

31. Siegfried Expands Production Capacity For Ophthalmic Drugs In El Masnou 5/23/2025

    Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.

32. Global Summit On Microphysiological Systems Research Set To Shape The Future Of Drug Development And Disease Modeling 5/22/2025

    The 4th Annual MPS World Summit, hosted by the International MPS Society (IMPSS) and supported by EUROoCS, will take place in Brussels, Belgium this summer.

33. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-1418, A Potential Best-In-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate 5/22/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418 (DB-1418), a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC).

34. GATC Health Paper Quantifies AI-Driven Capital Efficiencies And Advances Human-Centered Drug Discovery 5/22/2025

    GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine.

35. Sanofi To Acquire Vigil Neuroscience, Inc., Adding A New Investigational Medicine To Treat Alzheimer's Disease To The Neurology Pipeline 5/21/2025

    Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.

36. Genetic Mutations In Potassium Ion Channel Target Of New Drug Development 5/21/2025

    Ion channels are involved in almost everything our bodies do, from regular heartbeats to muscle function to allowing communication within the body. When something goes awry in the ion channels, it can have devastating effects on the body.

37. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-023 (ARTS-023), A Potential Best-In-Class, Novel CDK4 Selective Inhibitor 5/21/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-023 (formerly ARTS-023), a potential best-in-class, novel cyclin-dependent kinase 4 (CDK4) selective inhibitor.

38. Quantum Biopharma Announces Signing Of An Agreement With A Global Pharmaceutical Contract Research Organization To Prepare An IND (Investigational New Drug) Application Package For Lucid-21-302 (Lucid-MS), A First-In-Class Treatment For Multiple Sclerosis 5/20/2025

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA.

39. Candidate Drug That Boosts Protective Brain Protein In Mice Has Potential To Treat Alzheimer's Disease 5/20/2025

    As researchers work to improve treatment of Alzheimer’s disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the disease and improved memory in mice by boosting production of a protective protein.

40. Scientists Discover Potential New Targets For Alzheimer's Drugs 5/20/2025

    By combining information from many large datasets, MIT researchers have identified several new potential targets for treating or preventing Alzheimer’s disease.